Nephron

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, November 14, 2023

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • “Recent clinical and regulatory successes have significantly improved and strengthened our company’s prospects,” said Eric Schlorff, SeaStar Medical CEO.
  • SeaStar Medical expects regulatory approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The Company issued two convertible notes each for $0.5 million in August 2023 and a third convertible note for $0.5 million in September 2023.

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

Retrieved on: 
Monday, November 6, 2023

Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.

Key Points: 
  • Recent CDC data suggest that more than 3 million Americans have active thoughts of suicide and more than 50,000 die from suicide each year.
  • "There are few efforts as important as playing a role - through research and development - in tackling the nation's mental health crisis," said Lou Kennedy CEO and owner of Nephron Pharmaceuticals.
  • "To this end, we are honored to partner with NRx Pharmaceuticals in a groundbreaking endeavor.
  • Together, we are advancing the production of single-dose, intravenous Ketamine, which could be a crucial breakthrough for the treatment of depression.

Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals

Retrieved on: 
Thursday, September 28, 2023

NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, issues a shareholder update from Robert Hayes, the Company’s Chief Executive Officer.

Key Points: 
  • I am pleased to update you on Sharps’ recently signed Asset Purchase Agreement to acquire the InjectEZ facility, a specialty prefillable syringe manufacturing facility, and the associated $400 Million 10-year purchase agreement with Nephron Pharmaceuticals.
  • In this letter, I will provide key highlights about the Company’s vision, the proposed transaction, and the Company’s ongoing operations.
  • Strategic Partnership with Nephron Continues:
    Our relationship with Nephron has strengthened since the signing of the initial agreement last year.
  • The agreement will leverage synergies from both companies and enable Sharps to commercially enter the prefilled syringe landscape with strength and ahead of plan.

Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals

Retrieved on: 
Tuesday, September 26, 2023

NEW YORK and WEST COLUMBIA, S.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033.

Key Points: 
  • This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for next-generation copolymer prefillable syringe systems.
  • “Recruiting Robert Hayes as our CEO two years ago was a substantial achievement for Sharps Technology and its shareholders.
  • This transaction enables Sharps to enter the highly profitable copolymer prefillable syringe segment, which has the highest growth in the syringe market place.
  • InjectEZ is a new state-of-the-art facility with fully automated syringe system manufacturing, packaging, and distribution in West Columbia, South Carolina.

SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Monday, August 14, 2023

DENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2023 and provides a business update.

Key Points: 
  • Management to hold a business update conference call on August 22 beginning at 4:00 p.m. Eastern time
    DENVER, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and six months ended June 30, 2023 and provides a business update.
  • SeaStar Medical anticipates approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The net loss for the second quarter of 2023 was $3.7 million, or $0.25 per share, compared with a net loss of $0.9 million, or $0.12 per share, for the second quarter of 2022.
  • SeaStar Medical management will host a business update conference call on Tuesday, August 22, 2023 beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and answer questions.

Nephron Announces Julie Rameas as Chief Procurement Officer

Retrieved on: 
Thursday, August 17, 2023

WEST COLUMBIA, S.C., Aug. 17, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer.

Key Points: 
  • WEST COLUMBIA, S.C., Aug. 17, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Julie Rameas as Chief Procurement Officer.
  • In her new role, Rameas will oversee all strategic sourcing and procurement activities.
  • Her rock star resume and body of work speaks for itself," said Nephron CEO and Owner Lou Kennedy.
  • Before joining the Nephron team, Rameas served as Senior Director of Global Strategic Procurement at Thermo Fisher Scientific, where she led spending activities for over 800 global sites, and managed multiple global expansion and construction projects.

Nephron Works to Resolve Nationwide Drug Shortage by Producing Vital Medications

Retrieved on: 
Tuesday, August 8, 2023

WEST COLUMBIA, S.C., Aug. 8, 2023 /PRNewswire/ -- Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.

Key Points: 
  • WEST COLUMBIA, S.C., Aug. 8, 2023 /PRNewswire/ -- Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.
  • The following medications are readily available for order through the Nephron online ordering portal:
    "As a nationwide leader in manufacturing lifesaving medication, we work hard every single day to help the federal government alleviate drug shortages - and to deliver hospitals and patients the treatments they deserve and expect in a timely manner," said Lou Kennedy, CEO and Owner of Nephron.
  • Nephron has over 25 years of sterile pharmaceutical manufacturing experience and operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America.
  • To place an order, customers can contact Nephron directly at [email protected] or 1-844-224-2225.

Sharps Technology Provides Update on Commercialization Activities and is Highlighted in Med Tech Outlook Feature Article

Retrieved on: 
Thursday, July 6, 2023

NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an update on commercialization activities and is highlighted in Med Tech Outlook feature article.

Key Points: 
  • NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces an update on commercialization activities and is highlighted in Med Tech Outlook feature article.
  • Med Tech Outlook named Sharps Technology, Inc. the “Top Safety Syringe Manufacturer in 2023” and featured the Company in a cover article in the July edition of the publication , which can be found HERE .
  • The article, entitled "Sharps Technology, Inc.: Modernizing Drug Delivery with Novel Safety Syringe System Innovations", reviews the Company's technology offerings, transformative partnership with Nephron Pharmaceuticals, its next generation polymer-based prefillable syringe systems, and strategy forward with commercialization.
  • “As we advance our commercialization strategy for Sharps’ specialty syringe systems, we are at a pivotal time in the Company’s history,” commented Robert Hayes, Sharps Technology CEO.

Nephron Announces New President of 503B Outsourcing Facility

Retrieved on: 
Thursday, June 8, 2023

WEST COLUMBIA, S.C., June 8, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.

Key Points: 
  • WEST COLUMBIA, S.C., June 8, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.
  • "That combination will be an invaluable asset to the Nephron team."
  • Prior to joining Nephron, Fortier was the Chief Pharmacy Officer at Massachusetts General Hospital in Boston.
  • The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs.

Nephron To Produce 0.5% Albuterol 5 mL, Alleviating Nationwide Shortage

Retrieved on: 
Wednesday, May 31, 2023

WEST COLUMBIA, S.C., May 31, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.

Key Points: 
  • WEST COLUMBIA, S.C., May 31, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.
  • Nephron received FDA approval for Albuterol 0.5% 0.5 mL in 2001 and now provides millions of doses per year to patients nationwide.
  • In addition to Albuterol 0.5% 0.5 mL produced by Nephron, Nephron 503B Outsourcing Facility is now offering a larger fill volume of this essential product directly to hospitals and medical facilities, in an effort to alleviate the nationwide shortage.
  • A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products.